Assess the Prognosis of Advanced Fibrosis due to NASH with a Simple Blood Test

Clinical Benefits of The Enhanced Liver Fibrosis (ELF™) Test

The Enhanced Liver Fibrosis test is a non-invasive blood test that measures three direct markers of fibrosis. Direct assessment of fibrosis has proven valuable for identifying patients at risk of progressing to cirrhosis and/or liver-related events.

The most widely studied direct marker is the ELF Test which can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker to identify the patients most at risk of progression to cirrhosis and LREs in patients with advanced fibrosis due to NASH.

ELF™ Test Now Included in Multiple Clinical Guidelines

American Association of Clinical Endocrinology logo

American Association of Clinical Endocrinology

  • ELF was strongly recommended in the 2022 NAFLD Clinical Practice Guidelines
  • ELF testing can be incorporated into a clinical decision pathway to identify NASH patients at risk of progressing to cirrhosis
American Gastroenterological Association logo

American Gastroenterological Association

  • ELF was included in the 2022 Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
  • An ELF score of ≥ 9.8 is valuable for prognostic decision making

Why choose the ELF Test?

Applicability in Different Patients/Conditions







Economic Health Value

(Cost effectiveness)

Add clinical value

Improve ease and frequency of prognostic evaluation




Simple Blood Test

Large Installed Base



Clinical Benefits of ELF

Ilustración de una enfermera recolectando un análisis de sangre en un paciente

Blood-based tests can readily support high-volume testing, do not require patient access to specialized imaging equipment or highly trained operators, and generally have lower incidence rates of failure and unreliable results reported for imaging modalities.1,2

  • Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.2,3
  • Improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and liver-related events.4
  • Enhance patient management with a blood test that facilitates more frequent prognostic assessments
Literature Compendium

This compendium highlights the ELF Test as a prognostic tool in those with advanced fibrosis due to NASH.

Subscription Button Icon
Be the first to know about our events, training, and news